Read, pause, explore

Retatrutide

Also listed as LY3437943

A reference to read with the sources beside you.

Product status: InvestigationalEvidence: Randomized evidence

Status as of . The reference fields below define the scope of these labels.

Filed under Metabolism for browsing.

Reference fields

Sources for these fields
Approval scope
Investigational; no FDA-approved product.
Route and formulation
Studied as a subcutaneous injection.
Mechanism
Activates GIP, GLP-1 and glucagon receptors.
Evidence
A randomized obesity trial was funded by Lilly.
Limits of the evidence
Trial averages do not predict an individual outcome.
Safety context
The trial reported gastrointestinal adverse events.

A closer reading

Make space for the question

Think of a result measured carefully in one setting and a result examined across different settings. Careful measurement can make the estimate within a setting precise, but does not by itself show what would happen elsewhere. If another setting gives a different result, the difference deserves explanation rather than immediate dismissal. Perhaps the underlying question changed; perhaps a relevant feature differed. These are possibilities to investigate, not conclusions to assume. Reading across settings means keeping their differences visible while asking whether the proposed explanation remains useful beyond the place where it was first examined.

Keep these questions nearby

  1. How precise is the estimate within the setting where it was obtained?
  2. Which features would need consideration before comparing results from different settings?
  3. Would a different result challenge the explanation or indicate a changed question?

Sources

The references below accompany the entry as a whole. Dates show when each source was checked.

  1. FDA GLP-1FDA · Checked
  2. JastreboffPubMed · Checked

Keep a little room for reading

Prepared by Healthy Pound Editorial Team. Educational reference; no clinical review is claimed. This page does not provide individual medical advice.